Catalyst Wire Dossier Catalyst Wire Dossier

RBD vaccine candidate (recombinant protein) for SARS-CoV-2

recombinant protein RBD vaccine candidate · Laboratorios Hipra, S.A.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for RBD vaccine candidate (recombinant protein) for SARS-CoV-2, covering 2023-03-01 to 2023-03-01. Get the full timeline:

Most recent: Clinical Trial Update: Safety and Immunogenicity Study of Recombinant Protein RBD Candidate Vaccine Against SARS-CoV-2 in Adult Healthy Volunteers (COVID-19) [Phase 1, Phase 2]

See pricing